Solifenacin Succinate + Placebo
ApprovedCompleted 0 views this week 0 watching⚡ Active
Interest: 43/100
43
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Overactive Bladder
Conditions
Overactive Bladder, Benign Prostate Hyperplasia, Transurethral Resection of Prostate, Photoselective Vaporization Prostatectomy
Trial Timeline
Dec 4, 2012 → Oct 24, 2013
NCT ID
NCT01747577About Solifenacin Succinate + Placebo
Solifenacin Succinate + Placebo is a approved stage product being developed by Astellas Pharma for Overactive Bladder. The current trial status is completed. This product is registered under clinical trial identifier NCT01747577. Target conditions include Overactive Bladder, Benign Prostate Hyperplasia, Transurethral Resection of Prostate.
What happened to similar drugs?
10 of 20 similar drugs in Overactive Bladder were approved
Approved (10) Terminated (1) Active (9)
Hype Score Breakdown
Clinical
20
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (4)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01777217 | Approved | Terminated |
| NCT01747577 | Approved | Completed |
| NCT01371994 | Approved | Completed |
| NCT00801944 | Phase 3 | Completed |
Competing Products
20 competing products in Overactive Bladder